Pyridine N-Oxide Crystal Forms for NaV1.8 Inhibition
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current treatments for neuropathic and osteoarthritis pain are inadequate, with existing drugs having limited efficacy and significant side effects, and there is a need for new analgesic mechanisms targeting voltage-gated sodium channels, particularly NaV1.8, which are involved in pain sensation and transmission.
Innovation Solution
Development of specific crystal forms of a compound represented by formula (I), characterized by distinct X-ray powder diffraction patterns, thermogravimetric analysis, and differential scanning calorimetry profiles, which act as a voltage-gated sodium channel blocker, potentially offering improved pain relief with reduced side effects.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If existing analgesic drugs (opioids, calcium channel modulators, tricyclic antidepressants) are used to treat neuropathic and osteoarthritis pain, then pain relief is achieved, but significant side effects and limited efficacy occur
Solution Approach 1:
The patent changes the molecular structure parameters of the analgesic compound by incorporating specific heterocyclic rings (pyridine, pyrimidine, triazine) with nitrogen-containing six-membered rings, and by adjusting substituent groups (aromatic rings, heteroaryl groups, carbonyl groups) at defined positions. This structural parameter optimization enables selective binding to NaV1.8 channels, achieving pain relief with reduced side effects compared to conventional drugs.
Solution Approach 2:
The patent creates composite molecular structures combining multiple functional moieties: nitrogen-containing heterocyclic cores fused with aromatic or heteroaryl substituents, and further combined with carbonyl-containing groups. This composite molecular design facilitates dual or triple binding interactions with sodium channel proteins, enhancing analgesic efficacy while maintaining safety profiles.
2Productivity
If conventional analgesic treatments are used for chronic pain patients, then some pain relief is achieved, but the number of patients receiving timely effective treatment remains low (about 85% do not receive timely treatment)
Solution Approach 1:
The patent segments the analgesic mechanism into specific molecular interaction sites on the NaV1.8 channel protein. The compound structure is divided into distinct binding modules: the nitrogen-containing heterocyclic core that interacts with the sodium channel pore, and the aromatic/heteroaryl substituents that bind to adjacent protein regions. This segmented binding approach enables high-affinity, selective inhibition of pain transmission pathways.
Solution Approach 2:
The patent introduces a novel class of intermediary compounds that mediate between pain stimulation and the nervous system's pain perception pathways. These compounds act as selective modulators of sodium channel function, interfering with the pain signal transmission process itself rather than merely suppressing symptoms, thereby achieving more reliable and timely pain relief.
3Reliability
If new analgesic mechanisms targeting voltage-gated sodium channels are developed, then improved pain relief with reduced side effects is potential, but the complexity of developing and characterizing new crystal forms increases
Solution Approach 1:
The patent systematically varies crystallographic parameters including unit cell dimensions, space group assignments, and molecular packing arrangements to generate distinct crystal forms. By controlling these parameters during crystallization processes, the patent achieves multiple polymorphic forms with different pharmacokinetic properties, enabling optimization of bioavailability and reduction of side effects while managing characterization complexity through structured parameter variation.
Data Source
AI summary
A crystal form of a pyridine nitrogen oxide compound and the use thereof. Specifically, the present invention relates to a crystal form of a compound of formula (I), a pharmaceutical composition and the use thereof.